Publications Database

Baribeau D. A. , Anagnostou E. (2014)

Social communication is an emerging target for pharmacotherapy in autism spectrum disorder: A review of the literature on potential agents.

Journal of Canadian Academic Child Adolescent Psychiatry

23(1), pp. 20-30.

Read Abstract (New Window) Read Full (New Window)

Brondino N. et al. (2016)

Pharmacological modulation of GABA function in autism spectrum disorders: A systematic review of human studies.

Journal of Autism and Developmental Disorders

March, 46(3), pp. 825-839.

Read Abstract (New Window)

Canitano R. (2015)

Mood stabilizers in children and adolescents with autism spectrum disorders.

Clinical Neuropharmacology

September, 38(5), pp. 177-182.

Read Abstract (New Window)

Hadjikhani N. et al. (2015)

Improving emotional face perception in autism with diuretic bumetanide: A proof-of-concept behavioral and functional brain imaging pilot study.

Autism

February, 19(2), pp. 149-157.

Read Abstract (New Window)

Lemonnier E. et al. (2012)

A randomised controlled trial of bumetanide in the treatment of autism in children.

Transcultural Psychiatry

Read Abstract (New Window)

Lemonnier E. et al. (2017)

Effects of bumetanide on neurobehavioral function in children and adolescents with autism spectrum disorders.

Translational Psychiatry

7 e. 1056.

Read Abstract (New Window) Read Full (New Window)

Lemonnier E. , Ben-Ari Y. (2010)

The diuretic bumetanide decreases autistic behaviour in five infants treated during 3 months with no side effects.

Acta Paediatrica

99(12), pp. 1885-1888

Read Abstract (New Window)

Lemonnier E. et al. (2013)

Treating Fragile X syndrome with the diuretic bumetanide: a case report.

Acta Paediatrica

102(6), pp. 288-290.

Read Abstract (New Window)

American Society of Health-System Pharmacists (2010)

Bumetanide.

Bethesda: MD: American Society of Health-System Pharmacists

Read Abstract (New Window)